MethylGene announced that Celgene has terminated their licensing agreement for oncology histone deacetylase inhibitors, including MGCD0103. As a result, MethylGene will reacquire the rights to these programs. Furthermore, the company announced that it will implement a strategic initiative to focus its resources on the clinical development of its proprietary pipeline. MethylGene release